A patient on amiodarone is diagnosed to have cornea verticillata. What should be management: (PGI Dec 2010)
The core concept here is the side effect of amiodarone. Amiodarone is a Class III antiarrhythmic, but it has various side effects. Cornea verticillata is a relatively common side effect, but it's usually not vision-threatening. So, the management might not require stopping the drug unless there's significant visual impairment.
The correct answer would likely be to continue amiodarone and monitor. But wait, sometimes the options might include stopping the drug. Let me think. If the options include stopping amiodarone, is that necessary? I think cornea verticillata doesn't require discontinuation unless the patient is symptomatic. Since it's not causing vision loss, management is observation.
Now, the incorrect options. Let's say options A, B, C, D are various actions. For example, Option A might be to discontinue amiodarone. But that's not necessary unless there's a severe reaction. Option B could be to start another medication, but that's not indicated. Option C might be to perform a corneal transplant, which is overkill. Option D might be to use a topical corticosteroid, which isn't effective here.
The clinical pearl here is that cornea verticillata due to amiodarone is benign and doesn't require treatment unless there's visual disturbance. The key is to differentiate it from other corneal issues that do require intervention. So the management is usually observation and ensuring the patient is aware that this is a side effect but not an emergency.
**Core Concept**
Amiodarone, a Class III antiarrhythmic drug, causes corneal verticillata due to deposition of the drug in corneal epithelial microvilli. This condition is benign and asymptomatic, requiring no intervention unless visual impairment occurs.
**Why the Correct Answer is Right**
Corneal verticillata is a hallmark side effect of amiodarone. The corneal deposits are lipid-soluble and bind to corneal microvilli, creating a whorled pattern visible under slit-lamp examination. Since this condition does not affect vision or corneal function, management involves **continued amiodarone therapy with regular ophthalmologic monitoring**. Discontinuation is unnecessary unless the patient develops severe corneal toxicity or visual symptoms.
**Why Each Wrong Option is Incorrect**
**Option A:** Discontinuing amiodarone is unwarranted as corneal verticillata is nonprogressive and does not impair vision.
**Option B:** Initiating corticosteroids is ineffective because the condition is not inflammatory.
**Option C:** Corneal transplantation is never indicated for this benign, non-destructive deposit.
**Option D:** Referral for urgent surgery is a classic distractor; corneal verticillata does not require surgical intervention.
**